Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 133.90
+7.50 (5.93%)
Mar 30, 2026, 1:04 PM HKT
Akeso Employees
Akeso had 3,761 employees as of December 31, 2025. The number of employees increased by 726 or 23.92% compared to the previous year.
Employees
3,761
Change
726
Growth
23.92%
Revenue / Employee
904.30K HKD
Profits / Employee
-329.32K HKD
Market Cap
116.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Jun 30, 2025 | 3,529 | - | - |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 23,056 |
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| 3SBio | 6,268 |
| Innovent Biologics | 6,190 |
| Shanghai Henlius Biotech | 3,537 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
Akeso News
- 3 days ago - Akeso Reports Full-Year 2025 Financial Results - PRNewsWire
- 5 days ago - Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab - PRNewsWire
- 14 days ago - Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance - PRNewsWire
- 25 days ago - Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results - PRNewsWire
- 25 days ago - Inovio (INO) Teams Up with Akeso for Groundbreaking Cancer Therapy Trial - GuruFocus
- 6 weeks ago - Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications - PRNewsWire
- 7 weeks ago - Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer - PRNewsWire
- 2 months ago - Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis - PRNewsWire